Liquidia Challenges Regulatory Exclusivity Affecting YUTREPIA™ Approval
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company committed to developing innovative therapies for patients with rare cardiopulmonary diseases, has recently filed a lawsuit in the U.S. District Court for the District of Columbia. This legal action seeks to contest a decision made by the United States Food and Drug Administration (FDA), which awarded three-year new clinical investigation exclusivity (NCI exclusivity) to Tyvaso DPI. This decision has significantly delayed the approval process for Liquidia's own YUTREPIA™ (treprostinil) inhalation powder.
Background on the Licensing and Approval Process
The FDA had previously granted tentative approval for YUTREPIA™, an inhalation powder designed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). However, with the FDA's recent decision to extend NCI exclusivity to Tyvaso DPI, the final approval for YUTREPIA has been postponed until after the exclusivity period concludes on May 23, 2025. This delay not only restricts market access but also adversely affects patient care and their treatment options.
CEO's Statement on Regulatory Decision
Dr. Roger Jeffs, Ph.D., the Chief Executive Officer of Liquidia, expressed his strong dissatisfaction with the FDA's recent decision. He argued that this ruling unfairly favors United Therapeutics by allowing them to impose additional regulatory exclusivity, thereby limiting competition and reducing patient choices. Dr. Jeffs highlighted that Congress intended for NCI exclusivity to be granted only for genuine innovations supported by substantial clinical evidence. Liquidia firmly believes that the FDA's decision to extend exclusivity to Tyvaso DPI should be reversed, allowing YUTREPIA to reach the market quickly for the benefit of patients.
Understanding Pulmonary Arterial Hypertension and Its Impact
Pulmonary arterial hypertension (PAH) is a rare and progressive condition characterized by the narrowing and hardening of the pulmonary arteries, which can lead to right heart failure and potentially life-threatening outcomes. In the United States, approximately 45,000 patients are diagnosed with PAH, and currently, there are no known cures. Existing treatment strategies focus on alleviating symptoms, slowing disease progression, and enhancing the quality of life for patients.
Interstitial Lung Disease and Its Relation to Pulmonary Hypertension
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) includes a range of pulmonary conditions, with up to 150 different diseases encompassed. The presence of PH in patients with ILD is linked to poorer survival rates. In the United States, the estimated prevalence of PH-ILD exceeds 60,000, although many underlying conditions may go undiagnosed, complicating accurate assessments of the patient population.
About YUTREPIA™ (treprostinil) Inhalation Powder
YUTREPIA is an inhaled dry-powder formulation of treprostinil, designed for user-friendliness with a compact delivery device. This product was developed using Liquidia’s PRINT technology, which produces precise and uniform particles to optimize delivery within the lungs during inhalation.
Clinical Studies and Ongoing Research
Liquidia has successfully completed the INSPIRE study, which evaluated the safety and pharmacology of this innovative treatment in patients who are new to inhaled treprostinil or transitioning from Tyvaso. Currently, YUTREPIA is being assessed in an open-label multicenter study called ASCENT, aimed at determining the safety and tolerability profile for patients experiencing PH-ILD. Previously, YUTREPIA was referred to as LIQ861 during its investigational phase.
Liquidia Corporation: Driving Innovation in Pulmonary Therapeutics
Liquidia Corporation is dedicated to developing groundbreaking therapies for individuals with rare cardiopulmonary diseases. The company’s mission focuses on creating innovative solutions to meet unmet medical needs in the field of pulmonary hypertension, while also leveraging its proprietary PRINT technology for broader applications. In addition to YUTREPIA™, Liquidia is advancing several products to enhance patient care, including an investigational sustainable-release formulation of treprostinil and the currently marketed generic Treprostinil Injection for PAH treatment.
Frequently Asked Questions
What is YUTREPIA™ used for?
YUTREPIA™ is an inhalation powder specifically formulated to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Why has the approval of YUTREPIA™ been delayed?
The FDA granted NCI exclusivity to Tyvaso DPI, which has resulted in a delay of the approval process for YUTREPIA™ until after this exclusivity period concludes.
What is NCI exclusivity?
NCI exclusivity is a regulatory status awarded by the FDA that incentivizes drug innovation by providing a period of exclusivity for new clinical studies that demonstrate safety and efficacy.
How does Liquidia plan to address the delay in YUTREPIA™ approval?
Liquidia has initiated legal proceedings to challenge the decision that granted exclusivity to Tyvaso DPI, with the goal of expediting the approval of YUTREPIA™ for patient access.
Who can I contact for more information about Liquidia Corporation?
For investor inquiries, please contact Jason Adair at 919.328.4350, or for media inquiries, reach out to Patrick Wallace at 919.328.4383.
